---
title: "The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults | TEVA Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287252210.md"
description: "The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults | TEVA Stock News"
datetime: "2026-05-21T08:30:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287252210.md)
  - [en](https://longbridge.com/en/news/287252210.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287252210.md)
---

# The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults | TEVA Stock News

The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults | TEVA Stock News

### Related Stocks

- [TEVA.US](https://longbridge.com/en/quote/TEVA.US.md)

## Related News & Research

- [Teva launches new online schizophrenia community project](https://longbridge.com/en/news/282857569.md)
- [Kickstarter just killed its new mature content rules](https://longbridge.com/en/news/286954763.md)
- [Grown Up Group Sets June 2026 AGM to Approve Results and Share Mandate](https://longbridge.com/en/news/286990715.md)
- [Autolus reports 59% response for obe-cel in B-ALL patients with extramedullary disease](https://longbridge.com/en/news/287273701.md)
- [09:15 ETNewport Healthcare's 2025 Outcomes Report Demonstrates Significant Improvements in Teen and Young Adult Mental Health Following Treatment](https://longbridge.com/en/news/286920260.md)